Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Clin Exp Rheumatol ; 41(3): 543-553, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-36916322

RESUMO

Recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So far, some autoimmune rheumatic disease (ARD) patients with COVID-19 have been treated with antiviral therapies or anti-SARS-CoV-2 antibody products. However, there is no homogeneous approach to these treatment strategies. This issue was addressed within the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) in a discussion among experts and patient's representatives in the context of the rare and complex connective tissue diseases (rCTDs) covered by the Network. ERN ReCONNET is one of the 24 ERNs launched by the European Commission in 2017 with the aim of tackling low prevalence and rare diseases that require highly specialised treatment and promoting concentration of knowledge and resources through virtual networks involving healthcare providers (HCPs) across the European Union (EU). Considering the urgent need to provide guidance not only to the rCTDs community, but also to the whole ARDs community, a multidisciplinary Task Force, including expert clinicians and European Patient Advocacy Group (ePAG) Advocates, was created in the framework of ERN ReCONNET with the aim of developing overarching principles (OP) and points-to-consider (PtC) on a homogenous approach to treat immunocompromised patients with ARDs (with a particular focus on CTDs) affected by COVID-19 using antiviral therapies and anti-SARS-CoV-2 antibody products. The present work reports the final OP and PtC agreed by the Task Force.


Assuntos
Doenças Autoimunes , COVID-19 , Síndrome do Desconforto Respiratório , Doenças Reumáticas , Humanos , Doenças Autoimunes/tratamento farmacológico , Doenças Reumáticas/tratamento farmacológico , Doenças Reumáticas/epidemiologia , Antivirais/uso terapêutico
2.
Clin Exp Rheumatol ; 40 Suppl 134(5): 3-11, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35349419

RESUMO

In order to address the main challenges related to the rare diseases (RDs) the European Commission launched the European Reference Networks (ERNs), virtual networks involving healthcare providers (HCPs) across Europe. The mission of the ERNs is to tackle low prevalence and RDs that require highly specialised treatment and a concentration of knowledge and resources. In fact, ERNs offer the potential to give patients and healthcare professionals across the EU access to the best expertise and timely exchange of lifesaving knowledge, trying to make the knowledge travelling more than patients. For this reason, ERNs were established as concrete European infrastructures, and this is particularly crucial in the framework of rare and complex diseases in which no country alone has the whole knowledge and capacity to treat all types of patients.It has been five years since their kick-off launch in Vilnius in 2017. The 24 ERNs have been intensively working on different transversal areas, including patient management, education, clinical practice guidelines, patients' care pathways and many other fundamental topics. The present work is therefore aimed not only at reporting a summary of the main activities and milestones reached so far, but also at celebrating the first 5 years of the ERN on Rare and Complex Connective Tissue and Musculo-skeletal Diseases (ReCONNET), in which the members of the network built together one of the 24 infrastructures that are hopefully going to change the scenario of rare diseases across the EU.


Assuntos
Doenças Musculoesqueléticas , Doenças Raras , Tecido Conjuntivo , Europa (Continente) , Pessoal de Saúde , Humanos , Doenças Musculoesqueléticas/diagnóstico , Doenças Musculoesqueléticas/terapia , Doenças Raras/epidemiologia , Doenças Raras/terapia
3.
Lancet Rheumatol ; 6(8): e560-e572, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38876128

RESUMO

Rheumatic and musculoskeletal diseases often affect individuals of childbearing age. The incidence and prevalence of rheumatic and musculoskeletal diseases is rising. More pregnancies in patients with rheumatic and musculoskeletal diseases are anticipated and some rheumatic and musculoskeletal diseases are associated with pregnancy complications (eg, miscarriages, fetal deaths, preterm births, and hypertensive disorders in pregnancy). Despite the need to understand the use of drugs to treat rheumatic and musculoskeletal diseases in pregnancy, clinical trials in pregnancy are rare, therapeutics in pregnancy are understudied, and pregnant individuals are routinely excluded as premarketing trial participants. Data on the effectiveness and safety of disease-modifying antirheumatic drugs are most often based on post-marketing observational data. Observational studies assessing the bidirectional relationship between rheumatic and musculoskeletal diseases and pregnancy, as well as interventional studies of treatments during pregnancy, are scarce. Historical reluctance to perform studies in what was deemed an at-risk group persists in pharmaceutical companies, regulatory bodies, and ethics boards. Additionally, patients must be engaged partners, which requires trust that the research respects the needs and interests of the patient and complies with the rules intended to protect the pregnant person and the fetus from harm. In this Series paper, we share challenges we have encountered in conducting prospective cohort studies and interventional trials of postmarketing approved medications, assessing pregnancy specific outcomes in pregnant women with rheumatic and musculoskeletal diseases in the EU, the UK, and the USA. We discuss the changing landscape around trials in pregnancy and present possible solutions to our challenges.


Assuntos
Ensaios Clínicos como Assunto , Complicações na Gravidez , Projetos de Pesquisa , Humanos , Gravidez , Feminino , Complicações na Gravidez/tratamento farmacológico , Complicações na Gravidez/epidemiologia , Estudos de Coortes , Doenças Reumáticas/tratamento farmacológico , Doenças Musculoesqueléticas/tratamento farmacológico , Doenças Musculoesqueléticas/terapia , Antirreumáticos/uso terapêutico
4.
RMD Open ; 8(2)2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36597980

RESUMO

OBJECTIVE: The aim of this work is to explore patient' unmet needs of rare and complex rheumatic tissue diseases (rCTDs) patients during pregnancy and its planning by means of the narrative-based medicine (NBM) approach. METHODS: A panel of nine rCTDs patients' representatives was identified to codesign a survey aimed at collecting the stories of rCTD patients who had one or more pregnancies/miscarriages. The results of the survey and the stories collected were analysed and discussed with a panel of patients' representatives to identify unmet needs, challenges and possible strategies to improve the care of rCTD patients. RESULTS: 129 replies were collected, and 112 stories were analysed. Several unmet needs in the management of pregnancy in rCTDs were identified, such as fragmentation of care among different centres, lack of education and awareness on rCTD pregnancies among midwifes, obstetricians and gynaecologists. The lack of receiving appropriate information and education on rCTDs pregnancy was also highlighted by patients and their families. The need for a holistic approach and the availability specialised pregnancy clinics with a multidisciplinary organisation as well as the provision of psychological support during all the phases around pregnancy was considered also a priority. CONCLUSION: The adoption of the NBM approach enabled a direct identification of unmet needs, and a list of possible actions was elaborated to improve the care of rCTD patients and their families in future initiatives.


Assuntos
Serviços de Planejamento Familiar , Medicina Narrativa , Doenças Reumáticas , Feminino , Humanos , Gravidez , Doenças Reumáticas/epidemiologia , Doenças Reumáticas/terapia , Necessidades e Demandas de Serviços de Saúde , Conhecimentos, Atitudes e Prática em Saúde
5.
Nat Rev Rheumatol ; 17(3): 177-184, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33408338

RESUMO

During the COVID-19 pandemic, the need to provide high-level care for a large number of patients with COVID-19 has affected resourcing for, and limited the routine care of, all other conditions. The impact of this health emergency is particularly relevant in the rare connective tissue diseases (rCTDs) communities, as discussed in this Perspective article by the multi-stakeholder European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). The clinical, organizational and health economic challenges faced by health-care providers, institutions, patients and their families during the SARS-CoV-2 outbreak have demonstrated the importance of ensuring continuity of care in the management of rCTDs, including adequate diagnostics and monitoring protocols, and highlighted the need for a structured emergency strategy. The vulnerability of patients with rCTDs needs to be taken into account when planning future health policies, in preparation for not only the post-COVID era, but also any possible new health emergencies.


Assuntos
COVID-19/epidemiologia , Doenças do Tecido Conjuntivo/epidemiologia , Atenção à Saúde/organização & administração , Pandemias , SARS-CoV-2 , Comorbidade , Doenças do Tecido Conjuntivo/terapia , Humanos
8.
In. México. Secretaría de Salud. Dirección General de Planificación Familiar. Curso de orientación sexual y salud reproductiva. México D.F, México. Secretaría de Salud, 24 feb. 1992. p.55-7.
Monografia em Espanhol | LILACS | ID: lil-135075

RESUMO

Presenta el desarrollo y cambios registrados en púberes, iniciándose este período en un margen más o menos amplio que transcurre de los 9 a los 13 años en las niñas y de los 11 a los 15 años en los varones. Cada muchacho y cada muchacha tiene su propio período de cambios, y la gama de diferencias individuales es amplia. Se da una visión general del funcionamiento de las glándulas endocrinas y su repercución física y emocional. Los cambios puberales femeninos: crecimiento del tejido mamario, el contorno femenino va redondeándose gradualmente debido al ensanchamiento de la pelvis y la distribución de tejido adiposo en las caderas y gluteos, aparece vello en el pubis y en los labios mayores, aproximadamente dos años después de que los senos empiezan a crecer aparece la menarquia, cuya aparición no garantiza la capacidad inmediata de engendrar, los estrógenos también dan lugar a un mayor crecimiento de los órganos genitales externos y se produce un patrón cíclico de las secreciones hormonales que es la menstruación. Los primeros cambios observables en el varón son el crecimiento del pene y los testículos así como la aparición del vello en la base del pene, al desarrollo del vello púbico le sigue el crecimiento del vello axilar y la aparición de un fino vello sobre el labio superior llamado bozo. El desarrollo del vello facial y torácico continúa, a veces, hasta después de los 20 años, ocurre el cambio de voz, hay un crecimiento global; dos años después del inicio de la pubertad el niño es capaz de eyacular, y se presentan los llamados sueños húmedos. Todos los cambios físicos anteriormente descritos perturban la relativa tranquilidad de vida de los preadolescentes, y son el inicio de nuevas formas de relacionarse con el mundo, y de nuevas formas de pensar y sentir


Assuntos
Humanos , Caracteres Sexuais , Educação Sexual/classificação , Identidade de Gênero , Diferenciação Sexual , Comportamento Sexual/fisiologia , Educação Sexual/tendências , México , Comportamento Sexual/psicologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA